Skip to content

Sudden, severe headache? Call 911 (US)

HeadacheCare

Motrin Causes More Headaches for Johnson & Johnson

David Alexander M.D.Published May 28, 20102 min read
Motrin Causes More Headaches for Johnson & Johnson

Key points

  • Johnson & Johnson (JNJ) looks like it may need to take some Motrin to stave of the public-relations headache it’s facing.
  • To add insult to injury, the FDA reported it found 20 violations at a Johnson & Johnson plant in Ft.
  • This is bad news for Johnson & Johnson’s stock price because, after breaking out of its uptrend earlier this month, the stock is currently sitting at support around $60 – a level that was initially established in the latter half of 2009.
  • Credit Suisse, the last firm to issue a rating on Johnson & Johnson, reiterated its position with a neutral rating and gave the stock a price target of $61.

Johnson & Johnson (JNJ) looks like it may need to take some Motrin to stave of the public-relations headache it’s facing. Oh wait … maybe that’s not such a good idea. Motrin is the problem.

It turns out Johnson & Johnson learned about some problems with its Motrin formulas in November 2008. But instead of issuing a recall and letting the public know of the problem, Johnson & Johnson hired an outside contractor to go around and collect samples to see if the company should issue a full recall. Oops.

To add insult to injury, the FDA reported it found 20 violations at a Johnson & Johnson plant in Ft. Washington, Pa. – forcing the plant to close until it can bring its operations back up to code.

If you want to see how investors are reacting to the news, all you have to do is look at the Dow Jones Industrial Average. Johnson & Johnson is the only member of the 30 stocks that make up the Dow – which skyrocketed 2% higher right from the opening bell – that fell in early trading.

This is bad news for Johnson & Johnson’s stock price because, after breaking out of its uptrend earlier this month, the stock is currently sitting at support around $60 – a level that was initially established in the latter half of 2009. If the stock breaks down below this level, it will most likely not find support again until $55.

Looking ahead to next quarter’s earnings announcement, analysts expect Johnson & Johnson to earn $1.23 per share – which is 8 cents more than the company made during the same quarter last year.

Credit Suisse, the last firm to issue a rating on Johnson & Johnson, reiterated its position with a neutral rating and gave the stock a price target of $61.

Disclosure: Hansen does not own shares of the stocks discussed above. Positions can change without notice.

—

by Wade Hansen

Written by

David Alexander M.D.

Last updated

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. A sudden, severe headache, or one with weakness, confusion, fever or a stiff neck, needs emergency care: call 911 (US) or your local emergency number.

New Migraine Guidelines Rank Rx, OTC Efficacy
Managing Your Headaches

New Migraine Guidelines Rank Rx, OTC Efficacy

Seven different drugs are proven to be effective for preventing episodic migraine attacks and another half-dozen are probably helpful, according to new guidelines released here by the American Academy of Neurology (AAN). An evidence review by the AAN and the

6 min read

Migraines likelier in men with impotence
Managing Your Headaches

Migraines likelier in men with impotence

Men who have been diagnosed with erectile dysfunction are 63 percent more likely to also have had a diagnosis of migraine headaches than men without the sexual disorder, according to a new study from Taiwan. Dr. Tobias Köhler of Southern

4 min read

When a headache is an emergency

Know the warning signs.

Most headaches are not dangerous, but some need care right away. If you or someone near you has any of these, call 911 (US) or your local emergency number.